Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Adzynma Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Enzyme and Metabolic Disorder Therapies: Adzynma (ADAMTS13, recombinant-krhn)

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Adzynma under the MassHealth UPPL for members receiving medical-benefit therapy and establishes eligibility, documentation, dosing, prescriber, and continuation requirements for congenital thrombotic thrombocytopenic purpura.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyEnzyme and Metabolic Disorder Therapies: Adzynma
    Policy CodePolicy N/A
    Change TypeFormatting update
    Effective DateJan 4, 202748d
    Last ReviewJun 11, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for Adzynma under the MassHealth UPPL.
    SourceLink
    POLICY UPDATE CHANGES

    The review history describes the 2026 policy update as a formatting update.

    90 daysNew-plan lookback period
    ≥2 yearsMinimum authorization age
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum approval duration
    cTTPCovered diagnosis
    MedicalBenefit

    Authorization Criteria

    Authorization Criteria

    Authorization may be granted when the applicable pathway below is met.

    ONE of the following pathways

    • For a member new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days: medical records document that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via a manufacturer's patient assistance program.
    • ALL of the following criteria

      • Diagnosis of congenital thrombocytopenic purpura (cTTP).
      • Member is ≥ 2 years of age.
      • Prescriber is a hematologist, oncologist, or intensive care specialist, or consult notes from a specialist are provided.
      • Medical records or a copy of a genetic test confirm the diagnosis of cTTP (e.g., reduced ADAMTS13 activity).
      • Requested agent will not be used concurrently with fresh frozen plasma (FFP).
      • Dosing is appropriate within the FDA labeling.
      • Member's current weight is documented.

    Continuation Therapy

    Continuation of therapy requires resubmission by the prescriber.

    Resubmission documents a positive response to therapy or provides clinical rationale for continued use.

    Adzynma is not covered when used concurrently with fresh frozen plasma (FFP).

    Continuation Documentation

    Continuation Documentation

    Resubmission by the prescriber must document one of the following:

    Continuation documentation

    • Positive response: Member has demonstrated a positive response to therapy.
    • Clinical rationale supports continued use of Adzynma.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Adzynma under the MassHealth UPPL. The therapy is covered under the medical benefit, not the pharmacy benefit.

    • MassHealth UPPL applies.
    • Medical benefit coverage; no pharmacy benefit.
    • Medical benefit specialty limitations: phone 833-895-2611; fax 888-656-6671.
    Documentation Required

    New-Plan Current-Treatment Records

    For members whose coverage became effective within the prior 90 days, submit medical records documenting that the member is currently receiving the requested drug. This requirement does not apply when the product was obtained as samples or through a manufacturer’s patient assistance program.

    • Applies when coverage effective date is less than or equal to 90 days.

    Therapy Overview

    Adzynma (recombinant ADAMTS13) is an enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP). It is used for prophylactic or on-demand treatment in adult and pediatric patients with cTTP. This policy establishes prior authorization requirements for medical-benefit therapy, including diagnostic confirmation and, for continuation therapy, documentation of a positive response or clinical rationale for ongoing treatment.

    Key Terms

    cTTP
    TermCongenital thrombotic thrombocytopenic purpura
    AbbreviationcTTP
    DescriptionAn inherited condition treated with recombinant ADAMTS13 enzyme replacement therapy.
    ERT
    TermEnzyme replacement therapy
    AbbreviationERT
    Application to AdzynmaAdzynma (ADAMTS13, recombinant-krhn) is an ERT FDA-approved for prophylactic or on-demand treatment of adult and pediatric patients with cTTP.
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyEnzyme and Metabolic Disorder Therapies: Adzynma
    Policy CodePolicy N/A
    Change TypeFormatting update
    Effective DateJan 4, 202748d
    Last ReviewJun 11, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for Adzynma under the MassHealth UPPL.
    SourceLink
    On This Page
    Authorization CriteriaContinuation DocumentationAuthorization and Documentation RequirementsTherapy OverviewKey Terms
  1. Records must document current treatment with the requested drug.
  2. Exclude treatment obtained through samples or manufacturer patient assistance programs.
  3. Documentation Required

    Diagnosis and Weight Documentation

    Document the member’s diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP) and current weight as part of the authorization request.

    • Medical records or genetic testing must confirm cTTP, such as reduced ADAMTS13 activity.
    • Include the member’s current weight.
    Documentation Required

    Specialist Prescriber or Consultation

    The prescriber must be a hematologist, oncologist, or intensive care specialist, or the submission must include consultation notes from a qualifying specialist.

    • Qualifying prescriber: hematologist, oncologist, or intensive care specialist.
    • Alternatively, provide consultation notes from a qualifying specialist.
    Documentation Required

    Renewal Response Documentation

    At resubmission, the prescriber must document a positive response to therapy or provide clinical rationale for continued use.

    • Document positive response to therapy; or
    • Provide clinical rationale for continued treatment.
    Denial Risk

    Clinical Eligibility or Documentation Not Met

    Authorization may be denied when clinical eligibility or required documentation is not met. The request must satisfy the diagnosis, age, specialist, treatment-use, dosing, and documentation requirements.

    • Member must have cTTP and be at least 2 years of age.
    • Requested agent must not be used concurrently with fresh frozen plasma (FFP).
    • Dosing must be appropriate within FDA labeling.
    • Required medical records, genetic-test confirmation, specialist documentation, and current weight must be submitted.
    Denial Risk

    Current Treatment Not Documented

    For new-plan members, failure to submit records showing current treatment with the requested drug may result in denial, subject to the exception for treatment obtained through samples or a manufacturer’s patient assistance program.

    • Applies when coverage effective date is less than or equal to 90 days.
    • Submit current-treatment records unless the product was obtained as samples or through manufacturer patient assistance.
    Denial Risk

    Continuation Response or Rationale Missing

    A continuation request may be denied if the resubmission does not document a positive response to therapy or provide clinical rationale for continued use.

    • Document positive response to therapy; or
    • Provide clinical rationale for continued use.